CSL’s stock price has increased 29% over the past year and 105% since our initial Buy recommendation on 18 Mar 11 (Long Term Buy – $33.97), and is currently hovering around our Sell price of $70. That puts it on a seemingly expensive price-to-earnings ratio of 26, but as we're loath to let go of such a high quality company we want to analyse CSL’s interim results before considering a downgrade and selling the shares from our model Growth Portfolio. They're due on 12 Feb 14. The stock is up 4% since CSL's next gen a blood curdler from 10 Dec 13 (Hold – $67.39) and for now we're sticking with HOLD.
Note: The model Growth Portfolio owns shares in CSL.